MA32687B1 - Emulsions à libération modifiée destinées à une application sur la peau ou la muqueuse vaginale - Google Patents

Emulsions à libération modifiée destinées à une application sur la peau ou la muqueuse vaginale

Info

Publication number
MA32687B1
MA32687B1 MA33736A MA33736A MA32687B1 MA 32687 B1 MA32687 B1 MA 32687B1 MA 33736 A MA33736 A MA 33736A MA 33736 A MA33736 A MA 33736A MA 32687 B1 MA32687 B1 MA 32687B1
Authority
MA
Morocco
Prior art keywords
modified release
skin
application
vaginal mucosa
emulsions
Prior art date
Application number
MA33736A
Other languages
Arabic (ar)
English (en)
French (fr)
Inventor
Emanuela Mura
Federico Mailland
Daniela Ceriani
Original Assignee
Polichem Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40340663&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA32687(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Polichem Sa filed Critical Polichem Sa
Publication of MA32687B1 publication Critical patent/MA32687B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/345—Nitrofurans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Reproductive Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Colloid Chemistry (AREA)
MA33736A 2008-10-08 2011-04-01 Emulsions à libération modifiée destinées à une application sur la peau ou la muqueuse vaginale MA32687B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08166058A EP2174650A1 (en) 2008-10-08 2008-10-08 Modified release emulsions for application to skin or vaginal mucosa
PCT/EP2009/062190 WO2010040632A1 (en) 2008-10-08 2009-09-21 Modified release emulsions for application to skin or vaginal mucosa

Publications (1)

Publication Number Publication Date
MA32687B1 true MA32687B1 (fr) 2011-10-02

Family

ID=40340663

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33736A MA32687B1 (fr) 2008-10-08 2011-04-01 Emulsions à libération modifiée destinées à une application sur la peau ou la muqueuse vaginale

Country Status (19)

Country Link
US (1) US20110195944A1 (enExample)
EP (2) EP2174650A1 (enExample)
JP (1) JP2012505171A (enExample)
KR (1) KR20110067115A (enExample)
CN (1) CN102170862A (enExample)
AR (1) AR073801A1 (enExample)
AU (1) AU2009301275A1 (enExample)
BR (1) BRPI0920565A2 (enExample)
CA (1) CA2737255A1 (enExample)
CL (1) CL2011000767A1 (enExample)
CO (1) CO6361898A2 (enExample)
EA (1) EA201170555A1 (enExample)
IL (1) IL211681A0 (enExample)
MA (1) MA32687B1 (enExample)
MX (1) MX2011003696A (enExample)
NZ (1) NZ591919A (enExample)
PE (1) PE20110449A1 (enExample)
WO (1) WO2010040632A1 (enExample)
ZA (1) ZA201101818B (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2667852B1 (en) * 2011-01-27 2016-11-09 GlaxoSmithKline Biologicals SA Adjuvant nanoemulsions with crystallisation inhibitors
KR20140024292A (ko) 2011-04-01 2014-02-28 유니버시티 오브 플로리다 리서치 파운데이션, 인크. 치료제의 국소 전달용 감열성, 점막부착성 또는 표피부착성, 및 침투강화성 제제
DE102011076869A1 (de) * 2011-06-01 2012-12-06 Beiersdorf Ag Emulsionszubereitungen mit verbesserten rheologischen Eigenschaften
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
RS62297B1 (sr) 2011-11-23 2021-09-30 Therapeuticsmd Inc Prirodne kombinovane hormonske supstitucione formulacije i terapije
CN110075310A (zh) 2011-12-20 2019-08-02 维奥姆治疗有限公司 用于治疗真菌感染的局部油组合物
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
KR101862448B1 (ko) * 2013-04-12 2018-05-29 바이옴 바이오사이언스 피브이티. 엘티디. 항균제의 조성물과 제제, 그 공정, 및 세균 감염을 치료하는 방법
WO2015138668A1 (en) * 2014-03-12 2015-09-17 Warner Chilcott Company, Llc Low-dose estradiol cream
JP2017516768A (ja) 2014-05-22 2017-06-22 セラピューティックスエムディー インコーポレーテッドＴｈｅｒａｐｅｕｔｉｃｓｍｄ， Ｉｎｃ． 天然の併用ホルモン補充療法剤及び療法
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
US9931349B2 (en) 2016-04-01 2018-04-03 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
JP7219712B2 (ja) * 2016-10-13 2023-02-08 キャタレント・ユーケー・スウィンドン・ザイディス・リミテッド 膣送達のための凍結乾燥医薬組成物
IL271596B2 (en) * 2017-06-22 2024-07-01 Viramal Ltd Emulsion compositions comprising danazol for use in the treatment of an endometrial disease or condition
EP3787656A1 (en) 2018-05-04 2021-03-10 The Procter & Gamble Company Compositions and methods for treating vaginal dryness
EP3659583B1 (en) 2018-11-30 2023-06-07 Viramal Limited A method of preparing a gelling agent, the gelling agent obtained thereby, and the use of said gelling agent

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002058689A1 (en) * 2000-12-05 2002-08-01 Childrens Hospital Los Angeles Pharmaceutical compositions of fenretinide having increased bioavailability and methods of using the same
AU2003218507A1 (en) * 2002-04-04 2003-10-20 Medicis Pharmaceutical Corporation Methods for treating rosacea with pyridones
US20060018937A1 (en) * 2002-10-25 2006-01-26 Foamix Ltd. Steroid kit and foamable composition and uses thereof
US20060233721A1 (en) * 2002-10-25 2006-10-19 Foamix Ltd. Foam containing unique oil globules
US20040087564A1 (en) * 2002-10-31 2004-05-06 Wright D. Craig Delivery composition and method
AU2006339311A1 (en) * 2005-06-07 2007-09-07 Foamix Ltd. Antibiotic kit and composition and uses thereof
US20070071705A1 (en) * 2005-09-29 2007-03-29 De Oliveira Monica A M Topical anti-microbial compositions
US20080075745A1 (en) * 2006-09-21 2008-03-27 Glenmark Pharmaceuticals Limited Topical pharmaceutical compositions containing ciclopirox or a pharmaceutically acceptable salt thereof

Also Published As

Publication number Publication date
PE20110449A1 (es) 2011-07-07
EP2331065A1 (en) 2011-06-15
CL2011000767A1 (es) 2011-06-17
EA201170555A1 (ru) 2011-12-30
AU2009301275A2 (en) 2011-04-28
BRPI0920565A2 (pt) 2015-12-29
ZA201101818B (en) 2012-05-30
AR073801A1 (es) 2010-12-01
CO6361898A2 (es) 2012-01-20
MX2011003696A (es) 2011-06-20
EP2174650A1 (en) 2010-04-14
WO2010040632A1 (en) 2010-04-15
NZ591919A (en) 2012-09-28
JP2012505171A (ja) 2012-03-01
IL211681A0 (en) 2011-06-30
CN102170862A (zh) 2011-08-31
KR20110067115A (ko) 2011-06-21
CA2737255A1 (en) 2010-04-15
US20110195944A1 (en) 2011-08-11
AU2009301275A1 (en) 2010-04-15

Similar Documents

Publication Publication Date Title
MA32687B1 (fr) Emulsions à libération modifiée destinées à une application sur la peau ou la muqueuse vaginale
Li et al. In vitro transdermal delivery of therapeutic antibodies using maltose microneedles
RU2469726C2 (ru) Композиции с контролируемым высвобождением на основе кортикостероидов для лечения ушных болезней
ES2402789T3 (es) Métodos, composicones y kits para tratar dolor y prurito
RU2498988C2 (ru) Ингибиторы активности протеинтирозинкиназы
FR2930140B1 (fr) Dispositif pour la conservation, la preparation extemporanee et l'administration d'un faible dosage de principe actif
WO2007117352A3 (en) Topical therapeutic delivery system
EA200601799A1 (ru) Гидразидсодержащие соединения - ингибиторы cftr и их применение
UY30373A1 (es) Derivados de fenilalanina, procedimientos de preparacion y aplicaciones
AR055363A1 (es) Formulaciones farmaceuticas que comprenden un beta 2- agonista de accion prolongada para administracion por nebulizacion
Wu et al. Tetramethylpyrazine nitrone reduces oxidative stress to alleviate cerebral vasospasm in experimental subarachnoid hemorrhage models
ATE554770T1 (de) Therapeutisches mittel gegen entzündliche darmerkrankungen
RU2424804C2 (ru) Комбинации, включающие ингибитор рецептора сэфр (сосудистого эндотелиального фактора роста) и агент, увеличивающий проницаемость
WO2008058220A2 (en) Transdermal drug delivery system
ATE364391T1 (de) Arzneiformulierung enthaltend ciclosporin und deren verwendung
Sant et al. Influence of oleic acid on the rheology and in vitro release of lumiracoxib from poloxamer gels
US20100041704A1 (en) Dermal compositions of substituted amides and the use thereof as medication for pain and pruritus
BRPI0403269A (pt) emulsão múltipla
WO2017006112A1 (en) Composition and methods of treatment
Kelmann et al. Pentyl gallate nanoemulsions as potential topical treatment of herpes labialis
US20140235685A1 (en) Pharmaceutical compositions comprising 4-bromo-n-(imidazolidin-2-ylidene)-1h-benzimidazol-5-amine for treating skin diseases
Li et al. Synergistic effect of 1, 4-cyclohexanediol and 1, 2-hexanediol on percutaneous absorption and penetration of metronidazole
ES2498521B1 (es) Formulaciones basadas en nanoemulsiones y su uso para el tratamiento de la obesidad
CN117379391A (zh) 组合物和治疗方法
HK1153674A (en) Modified release emulsions for application to skin or vaginal mucosa